<DOC>
	<DOCNO>NCT02496585</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , drug nintedanib combination steroid , lung . Furthermore , treatment ' side effect study together quality life . In addition , investigator would like determine whether find marker blood predict worsen lung injury .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Nintedanib ( BIBF 1120 ) + Prednisone Taper Patients With Radiation Pneumonitis</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Radiation Pneumonitis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Histologically/cytologically proven primary thoracic malignancy lung metastasis ( require biopsyproven ) treat definitive intent MSK Prior treatment thoracic radiotherapy complete &gt; 4 week ≤ 9 month prior enrollment Radiographic evidence radiation pneumonitis CT scan chest without contrast Newly diagnose clinical grade 2 high radiation pneumonitis accord CTCAE version 4.0 criterion Age≥18 year KPS &gt; 70 % Reduction acute toxicity radiation treatment grade 1 Written informed consent sign prior entry study Current oral steroid use &gt; 2 week prior registration Ongoing treatment radiotherapy thorax , cytotoxic biological therapy malignancy Persistent &gt; grade 1 esophagitis Mean esophageal radiation dose &gt; 45 Gy Diagnosis diffuse radiation pneumonitis Untreated symptomatic brain metastasis leptomeningeal disease Liver metastases Other active malignancy Radiographic evidence cavitary necrotic tumor local invasion major blood vessel Active chronic Hepatitis C and/or B infection Gastrointestinal disorder would interfere drug absorption AST , ALT &gt; 1.5x ULN and/or Bilirubin &gt; ULN 1.5 X ULN ≥ Grade 2 proteinuria , creatinine &gt; 1.5x ULN GFR &lt; 45 ml/min Other investigational therapy receive within 8 week prior screen visit Pregnant woman woman breast feed child bear potential use highly effective method birth control least one month prior enrollment1 Sexually active male commit birth control course study ( except partner childbearing potential ) Conditions may affect patient 's ability participate trial , e.g . know suspect active alcohol drug abuse Inherited predisposition bleed thrombosis , INR &gt; 2 , PT PTT &gt; 1.5x ULN History bleed disorder thrombotic event , e.g . hemorrhagic thrombotic event within 12 month , clinically significant tumorrelated hemoptysis , active gastrointestinal bleeding ulcer major injury surgery ANC &lt; 1.5 K/mcL , Platelets &lt; 100 K/mcL , Hemoglobin &lt; 9.0 g/dl Concomitant treatment follow drug : azathioprine , cyclophosphamide , cyclosporine , pirfenidone , full dose anticoagulation ( vitamin K antagonist , dabigatran , heparin ) , fibrinolysis high dose antiplatelet therapy ( ex . Plavix 150mg ) ^2 Myocardial infarction unstable angina within 6 1 month start nintedanib treatment , respectively Known inherited predisposition thrombosis Patient history thrombotic event within 12 month start nintedanib treatment Known predisposition bleed Patients fibrinolysis , fulldose therapeutic anticoagulation , high dose antiplatelet therapy Patients severe hepatic impairment History gastrointestinal perforation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Nintedanib ( BIBF 1120 )</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Radiation Pneumonitis</keyword>
</DOC>